Modified thiomer-based nanomedicines in management of ocular complications: a review

Thiomer-based nanomedicines provide a diverse approach to delivering ophthalmic drugs and controlling problems. The review digs into the development, characterization, and use of thiomer and modified thiomer-based nanomedicines. It emphasizes their biocompatibility, which ensures that they are safe to use in the body. It also emphasizes their mucoadhesive characteristics, which assist the drug stick to the mucosal surfaces of the eye, therefore increasing efficacy. The study also emphasizes the possibility of higher medication bioavailability, which means that more of the medicine will reach and influence the target region of the eye. This holistic strategy is intended to improve eye treatment outcomes. It examines the anatomy of the eye, the categorization of ocular diseases, and the challenges faced by existing drug delivery techniques. The review centres on the advancement and therapeutic potential of thiomer-based nanomedicines for the treatment of various eye conditions, such as glaucoma, diabetic retinopathy, and age-related macular degeneration. It describes the steps involved in developing and evaluating these nanomedicines, with a focus on their safety and efficacy as determined by toxicological, preclinical, and clinical assessments. Furthermore, the paper covers the regulatory requirements for the approval and use of these novel therapies. Future opportunities for thiomer-based nanomedicines are discussed, as well as potential problems such as manufacturing scalability and assuring consistent treatment effects. The goal is to improve the delivery and efficacy of medicines for these critical eye disorders, therefore enhancing patient care and quality of life.